Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
Asıl Yazarlar: | Keshav, S, Ungashe, S, Zheng, W, Belker, P, Wright, K, Schall, T |
---|---|
Materyal Türü: | Conference item |
Baskı/Yayın Bilgisi: |
2007
|
Benzer Materyaller
-
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Yazar:: Bekker, P, ve diğerleri
Baskı/Yayın Bilgisi: (2007) -
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
Yazar:: Walters, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010) -
MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
Yazar:: Ungashe, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008) -
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
Yazar:: Satish Keshav, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01) -
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
Yazar:: Bekker, P, ve diğerleri
Baskı/Yayın Bilgisi: (2009)